EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dabrafenib‐Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis

Jaanvi Mehta iD, Julianna Tolotta iD, Eleanor Matthews iD, Daniel Joffe iD, Safiyyah Bhatti iD, Lauren Banner iD, Jenna Mandel iD, Molly Wallace iD, Timothy Webster iD, Jason B Lee iD, Neda Nikbakht iD

Case Reports in Dermatological Medicine · 2026-01 · 2026 (1)

DOI: 10.1155/crdm/5004676 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Dermatological Medicine, online erschienen am 14.07.2026. Verfasst von Jaanvi Mehta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, jefferson.edu. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Langerhans cell histiocytosis (LCH) is a rare malignancy marked by clonal proliferation of Langerhans cells, with BRAF V600E mutations identified in over 50% of the cases. BRAF inhibitors (BRAFi), such as dabrafenib, have shown efficacy in treating BRAF V600E‐mutant LCH. However, BRAFi therapy is associated with cutaneous adverse effects, including the development of new melanocytic nevi, verrucae, and keratinocyte carcinoma (KC). This case report describes a 78‐year‐old woman with BRAF V600E‐mutant LCH who developed multiple dermatologic side effects following dabrafenib salvage therapy. Seven weeks into treatment, the patient presented with eruptive palmoplantar nevi, verrucae, and a basal cell carcinoma (BCC). Biopsies revealed endophytic verruca vulgaris and acral junctional melanocytic nevus. A previous history of KC and photodamage likely contributed to the development of BCC. Additionally, the patient experienced arthralgias and Dupuytren’s contracture, consistent with known BRAFi side effects. While the cutaneous manifestations observed here have been documented in BRAF V600E‐mutant melanoma, this case is unique in its presentation in LCH patients. This report emphasizes the need for routine dermatologic monitoring and awareness of potential skin malignancies and other side effects in adults undergoing BRAFi therapy for LCH.

Autor:innen und Institutionen

  • Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, jefferson.edu.
  • Department of Dermatology & Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, jefferson.edu.
  • Department of Hematology & Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA, jefferson.edu.

ORCID-Profile: Jaanvi Mehta, Julianna Tolotta, Eleanor Matthews, Daniel Joffe, Safiyyah Bhatti, Lauren Banner, Jenna Mandel, Molly Wallace, Timothy Webster, Jason B Lee, Neda Nikbakht

Zitieren

APA

Mehta, J., Tolotta, J., Matthews, E., Joffe, D., Bhatti, S., Banner, L., Mandel, J., Wallace, M., Webster, T., Lee, J. B., & Nikbakht, N. (2026). Dabrafenib‐Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis. Case Reports in Dermatological Medicine, 2026(1). https://doi.org/10.1155/crdm/5004676

Vancouver

Mehta J, Tolotta J, Matthews E, Joffe D, Bhatti S, Banner L, et al. Dabrafenib‐Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis. Case Reports in Dermatological Medicine. 2026;2026(1). doi:10.1155/crdm/5004676

BibTeX
@article{Mehta2026,
  author = {Mehta, Jaanvi and Tolotta, Julianna and Matthews, Eleanor and Joffe, Daniel and Bhatti, Safiyyah and Banner, Lauren and Mandel, Jenna and Wallace, Molly and Webster, Timothy and Lee, Jason B and Nikbakht, Neda},
  title = {Dabrafenib‐Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis},
  journal = {Case Reports in Dermatological Medicine},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crdm/5004676}
}
Kostenlos starten →